STE
VENTE TOTALE: 4 058 titres (~956 795,24 $ US)
- Insiders
- Sohi Mohsen
- Total bought
- —
- Total sold
- $956,795
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-13
STE exhibits genuinely strong financial fundamentals — robust deleveraging, margin expansion, and improved cash conversion support a high health score of ~82.5 — but the event-driven catalyst is effectively absent…
The first sentence of the analysis written for STE on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 44.2% | 44.0% | 43.2% | 43.7% | 44.6% | |
| Ebit Margin | 18.7% | 16.2% | 16.5% | 17.9% | 10.8% | |
| Ebitda Margin | 26.9% | 24.9% | 27.5% | 27.2% | 23.9% | |
| Operating Profit Margin | 18.6% | 15.9% | 16.3% | 17.4% | 11.3% | |
| Pretax Profit Margin | 17.6% | 14.6% | 13.7% | 15.0% | 8.7% | |
| Continuous Operations Profit Margin | 13.2% | 11.2% | 10.8% | 12.3% | 6.7% | |
| Net Profit Margin | 13.2% | 11.3% | 7.4% | 2.4% | 5.8% | |
| Bottom Line Profit Margin | 13.2% | 11.3% | 7.4% | 2.4% | 5.8% | |
| Current Ratio | 2.091 | 1.957 | 3.081 | 2.334 | 2.037 | |
| Quick Ratio | 1.540 | 1.389 | 2.357 | 1.633 | 1.414 | |
| Solvency Ratio | 0.359 | 0.309 | 0.199 | 0.112 | 0.163 | |
| Cash Ratio | 0.384 | 0.168 | 0.222 | 0.242 | 0.378 | |
| Price To Earnings Ratio | 27.885 | 36.322 | 57.710 | 178.766 | 96.708 | |
| Price To Earnings Growth Ratio | 1.030 | 0.577 | 0.224 | -3.125 | -2.086 | |
| Forward Price To Earnings Growth Ratio | 1.030 | 0.577 | 0.224 | -3.125 | -2.086 | |
| Price To Earnings Diluted Ratio | 27.885 | 36.556 | 58.013 | 178.766 | 97.488 | |
| Price To Earnings Diluted Growth Ratio | 0.999 | 0.583 | 0.227 | -3.144 | -2.099 | |
| Price To Book Ratio | 3.023 | 3.383 | 3.465 | 3.138 | 3.610 | |
| Price To Sales Ratio | 3.658 | 4.092 | 4.249 | 4.204 | 5.583 | |
| Price To Free Cash Flow Ratio | 22.331 | 28.717 | 35.623 | 48.286 | 59.361 | |
| Price To Operating Cash Flow Ratio | 16.188 | 19.460 | 22.434 | 25.196 | 34.434 | |
| Debt To Assets Ratio | 0.194 | 0.217 | 0.306 | 0.300 | 0.287 | |
| Debt To Equity Ratio | 0.291 | 0.334 | 0.537 | 0.535 | 0.502 | |
| Debt To Capital Ratio | 0.225 | 0.250 | 0.349 | 0.348 | 0.334 | |
| Long Term Debt To Capital Ratio | 0.202 | 0.225 | 0.331 | 0.332 | 0.311 | |
| Financial Leverage Ratio | 1.495 | 1.537 | 1.756 | 1.781 | 1.749 | |
| Working Capital Turnover Ratio | 5.328 | 3.744 | 3.329 | 4.307 | 5.310 | |
| Operating Cash Flow Ratio | 1.172 | 1.123 | 1.045 | 0.878 | 0.743 | |
| Operating Cash Flow Sales Ratio | 0.226 | 0.210 | 0.189 | 0.167 | 0.162 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.725 | 0.678 | 0.630 | 0.522 | 0.580 | |
| Debt Service Coverage Ratio | 6.185 | 5.557 | 5.484 | 6.500 | 3.990 | |
| Interest Coverage Ratio | 18.152 | 10.047 | 5.792 | 7.138 | 5.339 | |
| Short Term Operating Cash Flow Coverage Ratio | 8.671 | 9.185 | 11.325 | 12.616 | 4.793 | |
| Operating Cash Flow Coverage Ratio | 0.643 | 0.521 | 0.288 | 0.233 | 0.209 | |
| Capital Expenditure Coverage Ratio | 3.635 | 3.102 | 2.701 | 2.091 | 2.381 | |
| Dividend Paid And Capex Coverage Ratio | 2.196 | 1.946 | 1.735 | 1.388 | 1.519 | |
| Dividend Payout Ratio | 0.308 | 0.358 | 0.530 | 1.714 | 0.669 | |
| Enterprise Value Multiple | 14.652 | 17.939 | 17.708 | 17.911 | 26.266 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 44.2% | ▲0.2% | ▲0.3% |
| Ebit Margin | 18.7% | ▲2.5% | ▲2.7% |
| Ebitda Margin | 26.9% | ▲2.0% | ▲0.8% |
| Operating Profit Margin | 18.6% | ▲2.7% | ▲2.7% |
| Pretax Profit Margin | 17.6% | ▲3.1% | ▲3.7% |
| Continuous Operations Profit Margin | 13.2% | ▲2.0% | ▲2.4% |
| Net Profit Margin | 13.2% | ▲2.0% | ▲5.2% |
| Bottom Line Profit Margin | 13.2% | ▲2.0% | ▲5.2% |
| Current Ratio | 2.091 | ▲0.134 | ▼-0.209 |
| Quick Ratio | 1.540 | ▲0.151 | ▼-0.127 |
| Solvency Ratio | 0.359 | ▲0.050 | ▲0.131 |
| Cash Ratio | 0.384 | ▲0.216 | ▲0.105 |
| Price To Earnings Ratio | 27.885 | ▼-8.437 | ▼-51.593 |
| Price To Earnings Growth Ratio | 1.030 | ▲0.452 | ▲1.706 |
| Forward Price To Earnings Growth Ratio | 1.030 | ▲0.452 | ▲1.706 |
| Price To Earnings Diluted Ratio | 27.885 | ▼-8.671 | ▼-51.857 |
| Price To Earnings Diluted Growth Ratio | 0.999 | ▲0.417 | ▲1.686 |
| Price To Book Ratio | 3.023 | ▼-0.361 | ▼-0.301 |
| Price To Sales Ratio | 3.658 | ▼-0.434 | ▼-0.699 |
| Price To Free Cash Flow Ratio | 22.331 | ▼-6.386 | ▼-16.532 |
| Price To Operating Cash Flow Ratio | 16.188 | ▼-3.272 | ▼-7.354 |
| Debt To Assets Ratio | 0.194 | ▼-0.023 | ▼-0.067 |
| Debt To Equity Ratio | 0.290 | ▼-0.043 | ▼-0.149 |
| Debt To Capital Ratio | 0.225 | ▼-0.025 | ▼-0.076 |
| Long Term Debt To Capital Ratio | 0.202 | ▼-0.024 | ▼-0.079 |
| Financial Leverage Ratio | 1.495 | ▼-0.042 | ▼-0.169 |
| Working Capital Turnover Ratio | 5.328 | ▲1.584 | ▲0.924 |
| Operating Cash Flow Ratio | 1.171 | ▲0.048 | ▲0.179 |
| Operating Cash Flow Sales Ratio | 0.226 | ▲0.016 | ▲0.035 |
| Free Cash Flow Operating Cash Flow Ratio | 0.725 | ▲0.047 | ▲0.098 |
| Debt Service Coverage Ratio | 6.185 | ▲0.628 | ▲0.642 |
| Interest Coverage Ratio | 18.152 | ▲8.105 | ▲8.858 |
| Short Term Operating Cash Flow Coverage Ratio | 8.671 | ▼-0.514 | ▼-0.647 |
| Operating Cash Flow Coverage Ratio | 0.643 | ▲0.121 | ▲0.264 |
| Capital Expenditure Coverage Ratio | 3.635 | ▲0.533 | ▲0.853 |
| Dividend Paid And Capex Coverage Ratio | 2.196 | ▲0.250 | ▲0.439 |
| Dividend Payout Ratio | 0.308 | ▼-0.050 | ▼-0.408 |
| Enterprise Value Multiple | 14.652 | ▼-3.287 | ▼-4.243 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $21.71B | $22.34B | $21.83B | $19.07B | $23.58B | |
| Enterprise value | $23.36B | $24.37B | $25.01B | $22.11B | $26.51B | |
| EV / Sales | 3.94x | 4.46x | 4.87x | 4.87x | 6.28x | |
| EV / Op. cash flow | 17.42x | 21.23x | 25.70x | 29.21x | 38.72x | |
| EV / Free cash flow | 24.03x | 31.33x | 40.80x | 55.98x | 66.74x | |
| EV / EBITDA | 14.65x | 17.94x | 17.71x | 17.91x | 26.27x | |
| Net debt / EBITDA | 1.03x | 1.50x | 2.25x | 2.46x | 2.90x | |
| Current ratio | 2.09x | 1.96x | 3.08x | 2.33x | 2.04x | |
| Income quality | 1.71x | 1.86x | 2.56x | 7.15x | 2.82x | |
| Graham number | $115 | $97 | $74 | $38 | $61 | |
| Graham net-net | -$20 | -$23 | -$35 | -$36 | -$37 | |
| Tax burden | 75.0% | 77.2% | 53.8% | 15.7% | 66.5% | |
| Interest burden | 94.5% | 90.2% | 83.0% | 83.8% | 80.4% | |
| Working capital | $1.25B | $978.6M | $1.94B | $1.15B | $956.8M | |
| Invested capital | $9.38B | $9.04B | $10.07B | $8.90B | $10.43B | |
| Return on assets | 7.3% | 6.1% | 3.4% | 1.0% | 2.1% | |
| Operating ROA | 10.6% | 8.2% | 7.6% | 7.1% | 5.3% | |
| Return on tangible assets | 15.9% | 14.6% | 7.8% | 2.2% | 6.6% | |
| Return on equity | 10.9% | 9.3% | 6.0% | 1.8% | 3.7% | |
| Return on invested capital | 8.5% | 7.2% | 6.4% | 6.4% | 3.5% | |
| Return on capital employed | 11.5% | 9.5% | 8.3% | 7.9% | 4.6% | |
| Earnings yield | 3.6% | 2.8% | 1.7% | 0.6% | 1.0% | |
| Free cash flow yield | 4.5% | 3.5% | 2.8% | 2.1% | 1.7% | |
| Capex / Op. cash flow | 27.5% | 32.2% | 37.0% | 47.8% | 42.0% | |
| Capex / Depreciation | 75.8% | 77.7% | 63.7% | 65.5% | 52.0% | |
| Capex / Sales | 6.2% | 6.8% | 7.0% | 8.0% | 6.8% | |
| SG&A / Sales | 23.7% | 24.4% | 24.4% | 24.0% | 31.2% | |
| R&D / Sales | 1.9% | 2.0% | 2.0% | 2.2% | 2.1% | |
| Stock comp / Sales | 1.0% | 1.1% | 1.1% | 0.9% | 1.4% | |
| Intangibles / Total assets | 54.2% | 58.6% | 55.9% | 55.0% | 67.7% | |
| Days sales outstanding | 67d | 70d | 72d | 70d | 69d | |
| Days payables outstanding | 37d | 34d | 31d | 38d | 35d | |
| Operating cycle | 137d | 139d | 156d | 156d | 159d | |
| Cash conversion cycle | 100d | 106d | 124d | 118d | 124d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-2.8%EV / Sales ▼-11.8%EV / EBITDA ▼-18.3%EV / Op. cash flow ▼-3.813Earnings yield ▲+0.009Graham number ▲+17.770
Profitability
Return on equity ▲+0.016Return on assets ▲+0.013Return on invested capital ▲+0.013Return on capital employed ▲+0.020Operating ROA ▲+0.024Income quality ▼-0.155Tax burden ▼-0.022
Efficiency
Days sales outstanding ▼-2.598Days payables outstanding ▲+3.841Operating cycle ▼-2.331Cash conversion cycle ▼-6.172Capex / Sales ▼-0.006R&D / Sales ▼-0.001
Balance-sheet strength
Current ratio ▲+0.134Net debt / EBITDA ▼-0.461Working capital ▲+271008000.000Invested capital ▲+339208000.000Intangibles / Total assets ▼-0.045
Change over 5 years
Valuation
Market cap ▼-7.9%EV / Sales ▼-37.3%EV / EBITDA ▼-44.2%EV / Op. cash flow ▼-21.299Earnings yield ▲+0.026Graham number ▲+53.328
Profitability
Return on equity ▲+0.072Return on assets ▲+0.052Return on invested capital ▲+0.050Return on capital employed ▲+0.069Operating ROA ▲+0.052Income quality ▼-1.111Tax burden ▲+0.085
Efficiency
Days sales outstanding ▼-1.859Days payables outstanding ▲+2.162Operating cycle ▼-21.852Cash conversion cycle ▼-24.013Capex / Sales ▼-0.006R&D / Sales ▼-0.001
Balance-sheet strength
Current ratio ▲+0.054Net debt / EBITDA ▼-1.871Working capital ▲+292825000.000Invested capital ▼-1049911000.000Intangibles / Total assets ▼-0.135
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-31 | April Delaney | Sale | $1,001 - $15,000 |
| 2026-07-29 | April Delaney | Sale | $1,001 - $15,000 |
| 2026-07-27 | April Delaney | Sale | $1,001 - $15,000 |
| 2026-07-24 | April Delaney | Sale | $1,001 - $15,000 |
| 2026-05-13 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-04-30 | April Delaney | Purchase | $1,001 - $15,000 |
| 2026-03-16 | April Delaney | Purchase | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-02-06 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-09-18 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-09-11 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-06-26 | April Delaney | Sale | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-08-11 STERIS Q1 Earnings Call Highlights STERIS (NYSE: STE) reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina. Total reported revenue increased 7% from the prior-year quarter, while constant-currency organic revenue rose 6%, driven by volume growth and 190
- 2026-08-09 STERIS Q1 Earnings Call Highlights STERIS NYSE: STE reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.
- 2026-08-06 STERIS plc (STE) Q1 2027 Earnings Call Transcript STERIS plc (STE) Q1 2027 Earnings Call Transcript
- 2026-08-06 STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
- 2026-08-06 5 Quality Stocks Set to Reward Investors With Dividend Hikes Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.
- 2026-08-05 Here''s What Key Metrics Tell Us About Steris (STE) Q1 Earnings While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-05 Steris (STE) Q1 Earnings Surpass Estimates Steris (STE) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.34 per share a year ago.
- 2026-08-05 STERIS Announces Financial Results for Fiscal 2027 First Quarter DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter.
- 2026-08-05 Steris to invest $600 million in new North Carolina chemicals manufacturing hub Medical equipment maker Steris said on Wednesday it will invest $600 million to build a manufacturing and distribution hub in North Carolina for chemicals used by healthcare and pharmaceutical customers.
- 2026-08-05 STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina • This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries